Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of SKF101804 Cefixime vs Reference in Healthy Adults
NCT03329547Phase 1Withdrawn
- Sponsor
- GSK
- Start
- Jan 2018
- Primary completion
- Feb 2018
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of cefixime in bacterial infection (2 arms), sponsored by GSK. Primary endpoints: Area under the concentration-time curve from time zero to last time of quantifiable concentration at 24 hours and Maximum observed concentration at 24 hours. Planned start Jan 2018; status: withdrawn.
02
Drugs
cefixime
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03329547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03329547.